A decision analysis evaluating screening for kidney cancer using focused renal ultrasound

Sabrina H. Rossi MBChB MPhil\textsuperscript{a,b,c}, Tobias Klatte MD PhD\textsuperscript{b,d}, Juliet A. Usher-Smith MB BChir PhD\textsuperscript{e}, Kate Fife MD\textsuperscript{b,c}, Sarah J. Welsh BMChB PhD\textsuperscript{b,c}, Saeed Dabestani MD PhD\textsuperscript{f}, Axel Bex MD PhD\textsuperscript{g,h}, David Nicol MBBS\textsuperscript{i,j}, Paul Nathan MBBS PhD\textsuperscript{k}, Grant D. Stewart MBChB PhD\textsuperscript{a,b,c*}, Edward C.F. Wilson PhD\textsuperscript{l,m*}

\textsuperscript{*}joint senior authors

\textsuperscript{a}Department of Surgery, University of Cambridge, Addenbrooke’s Hospital, Cambridge
\textsuperscript{b}Biomedical Campus, Cambridge, UK
\textsuperscript{c}Cambridge University Hospitals NHS Foundation Trust, Addenbrooke’s Hospital, Cambridge
\textsuperscript{d}Cambridge Biomedical Campus, Cambridge, UK
\textsuperscript{e}Department of Urology, Royal Bournemouth Hospital, Bournemouth, UK
\textsuperscript{f}The Primary Care Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
\textsuperscript{g}The Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer, UK
\textsuperscript{h}The Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer, UK
\textsuperscript{i}Lund University, Skane University Hospital, Department of Clinical Sciences Lund, Lund, Sweden
\textsuperscript{j}The Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer, UK
Corresponding authors:

Grant D Stewart, BSc MBChB PhD Edin, MA Cantab, FRCSEd (Urol)
Department of Surgery, University of Cambridge, Addenbrooke’s Hospital, Cambridge
Biomedical Campus, CB2 0QQ, Cambridge, UK
Email: gds35@cam.ac.uk
Telephone: 01223 245151

Edward CF Wilson BSc MSc PhD
Health Economics Group, Norwich Medical School, University of East Anglia, NR4 7TJ,
Norwich, UK
Email: Ed.Wilson@uea.ac.uk
Telephone: 01603 593620

**Running title:** Decision analysis of screening for renal cancer
Key words: Cost-effectiveness, Renal cell cancer, RCC, kidney cancer, Screening, Ultrasound

Funding: The Urology Foundation (SHR). Kidney Cancer UK (SHR and GDS). Renal Cancer Research Fund (SHR and GDS). CRUK Prevention Fellowship (C55650/A21464) (JUS). The funding sources had no role in data collection and analysis, nor the manuscript itself.

Financial Disclosure: PN has received consultancy fees from BMS, EUSA, Ipsen, MSD, Merck, Pfizer, Novartis. SDA has received honoraria from Pfizer and fees as medical advisor for Elypta AB. AB has received educational grants from Pfizer; consultancy fees from Pfizer, Roche, Novartis, BMS and EISAI. GDS has received educational grants from Pfizer, AstraZeneca and Intuitive Surgical; consultancy fees from Pfizer, Merck, EUSA Pharma and Cambridge Medical Robotics; Travel expenses from Pfizer and Speaker fees from Pfizer. All other authors have no financial disclosures.

Registration: Not applicable

Ethics: Health economics study not involving human participants therefore ethics approval not required.

Acknowledgements: We would like to thank Professors Simon Griffin and Vicky Goh, as well as Ms Christy Watson, our patient representative, for their input and advice. We would also
like to thank Kidney Cancer UK, The Renal Cancer Research Fund and The Urology Foundation for their support.

Abstract word count: 300/300

Manuscript word count: 2693/2500
Structured abstract

Background: Screening for renal cell carcinoma (RCC) has been identified as a key research priority; however, no randomised control trials have been performed. Value of information analysis can determine whether further research on this topic is of value.

Objectives: To determine (a) whether current evidence suggests screening is potentially cost-effective. If so, (b) in which age/sex groups, (c) identify evidence gaps and (d) estimate the value of further research to close those gaps.

Design, Setting, Participants: A decision model was developed evaluating screening in asymptomatic individuals in the UK. A National Health Service perspective was adopted.

Intervention: A single focused renal ultrasound scan compared with standard of care (no screening).

Outcome measures: Expected lifetime costs, quality adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER), discounted at 3.5%/annum.

Results: Given a prevalence of RCC of 0.34% (0.18-0.54%), screening 60 year-old men resulted in an ICER of £18,092/QALY[€22,843/QALY]. Given a prevalence of RCC of 0.16% (0.08-0.25%), screening 60-year-old women resulted in an ICER of £37,327/QALY[€47,129/QALY]. In the one-way sensitivity analysis, the ICER was <£30,000/QALY so long as the prevalence of RCC was ≥0.25% for men and ≥0.2% for women.
at age 60 years. Given a willingness to pay threshold of £30,000/QALY (€37,878/QALY), the population expected value of perfect information was £194 million (£244 million) and £97 million (£123 million) for 60-year-old men and women respectively. The expected value of perfect parameter information suggests the prevalence of RCC and stage shift associated with screening are key research priorities.

Conclusion: Current evidence suggests one-off screening of 60-year-old men is potentially cost-effective and that further research into this topic would be of value to society.

Patient Summary: Economic modelling suggests that screening 60-year-old men for kidney cancer using ultrasound may be a good use of resources and that further research on this topic should be performed.

**Word count: 300/300**
Introduction

Cost-effectiveness analyses (CEA) are classically performed to aid decisions regarding the value of implementing new interventions into a health service. More recently, value of information analyses (VOI) of screening interventions have been undertaken using the currently available evidence, prior to a large trial being undertaken, aiming to determine the value of investing future funds into further research[1]. Indeed, VOI has been used to examine uncertainty surrounding the optimal screening strategy for colorectal cancer and therefore prioritise future research efforts[2].

Screening for renal cell carcinoma (RCC) has repeatedly been identified as a research priority[3-6]. Over a quarter of individuals diagnosed with RCC have metastases at presentation. Five-year age standardized relative survival for these individuals is 6% compared to 84% for those with stage I disease[7]. Ultrasound has been proposed as a screening tool, as it is well tolerated, inexpensive and widely available[8]. National abdominal aortic aneurysm (AAA) screening programs for 65-year-old men are established in the UK and Sweden and have demonstrated that an ultrasound-based screening program can be delivered in the community by trained technicians[9, 10]. Observational studies evaluating screening for RCC using ultrasound have been conducted. However, none were randomised, and all were published more than a decade ago[11-18]. Due to the relatively low prevalence of RCC in unselected asymptomatic individuals, a randomised controlled trial (RCT) sufficiently powered to detect an impact on survival would need to recruit hundreds of thousands of participants[11]. Therefore, we perform a decision analysis synthesizing the
currently available evidence, with the aim of determining the value of performing further research into this topic.
Methods

Scope of the decision model

A cohort simulation model was developed adopting a UK National Health Service perspective, consistent with Consolidated Health Economic Evaluation Reporting Standards (Supplement)[19, 20]. The model compares screening (intervention) versus the standard of care (no screening) in asymptomatic individuals from the general population. Screening consists of a single focused renal ultrasound, delivered by technicians in the community, similar to AAA screening[21]. If the ultrasound is reported as normal or as a simple cyst, the patient is discharged. Any other abnormality is investigated with an outpatient urology clinic ± CT as appropriate (Supplemental Figure 1). The primary outcomes are the incremental costs (2016 £GBP), incremental quality adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) comparing one-off screening with no screening. The ICER was defined as the mean incremental costs divided by the mean incremental QALYs. A cycle length of one year and a lifetime time horizon were adopted. Costs and QALYs were discounted at 3.5%/annum. The UK willingness to pay threshold of £20,000–£30,000/QALY gained [€25,252–€37,878/QALY] was used; therefore, an ICER>£30,000 was considered not to be cost-effective [19, 20].

Model structure

The model, which consisted of a decision tree with Markov models at each terminal node, was developed in Microsoft Excel (2016). The decision tree demonstrates the disease status (i.e. RCC, no RCC, benign incidental finding) and the test result (true positive/negative, false
positive/negative). Figure 1 represents a simplified schematic of the Markov models (Supplemental Figures 2-7).

Model inputs

Model inputs were derived through comprehensive literature reviews and where no data were available, through structured expert elicitation (Table 1) [8, 11, 22, 23]. Further details are available in the Supplemental Methods.

A meta-analysis demonstrated that the pooled prevalence of RCC detected by ultrasound was more than twice as high in studies from Europe and North America compared to Asia (0.17% (0.09-0.27%) vs 0.06 (0.03-0.09%) (n=29,938)[11]. Only one study, by Mihara et al., reported the prevalence of RCC by age and sex, which screened Japanese individuals from 1983 to 1996 (overall prevalence of RCC: 0.09%)[14]. Although the study by Mihara et al. underestimates the true prevalence of RCC in a contemporary Western population, the relative prevalence by age and sex is likely to still be relevant[11, 14, 24]. Therefore, to derive likely prevalence rates in the UK by age and sex, the prevalence reported by Mihara et al. was used along with the results of the meta-analysis applied to the UK population reported by the Office for National Statistics (Table 1)[25].

The cost of AAA screening ultrasound in the UK is £37.53 [€47] [21]. In the base case, it was assumed screening renal ultrasound would have the same cost (Table 1). If ultrasound were to be performed by sonographers in secondary care, then it would be priced at £55 (IQR £38-£63) [€69], therefore this was evaluated in the sensitivity analysis[26].
No studies have evaluated the impact of screening for RCC on quality of life (QoL)[22]. Ultrasound screening for AAA and ovarian cancer was not associated with a disutility[27-31]. Therefore, ultrasound screening for RCC was assigned a disutility of 0 and this assumption was tested in the sensitivity analysis.

Model analysis

The decision model was run with 3000 Monte Carlo simulations as this achieved stability of results, defined as a coefficient of variation <2% for the SE of the incremental net monetary benefit[32]. In brief, this means a set of inputs was sampled from the respective distributions, the model calculated and repeated 3000 times to generate an empirical estimate of the uncertainty in cost-effectiveness. The ICER was evaluated for males and females aged 40, 50 and 60 years as estimates for prevalence of RCC were available for these groups based on the study by Mihara et al[14]. The population in whom screening is most cost-effective was determined from this and used as the base case for all subsequent analyses.

The expected value of perfect information (EVPI) and perfect parameter information (EVPPI) were determined. The EVPI summarises the value of eliminating all parameter uncertainty (i.e. perfect information), whereas the EVPPI summarises the value of eliminating individual parameter uncertainty[33, 34]. Thus, the EVPI provides an upper limit for all future research expenditure regarding the decision problem. The EVPPI determines the value of eliminating uncertainty in a parameter (or group of parameters), and so can be used to guide research
priorities[34]. The population VOI statistics were based on the number individuals eligible for screening[35]. The EVPPI was determined by running the simulation 1000 times for the inner loop and 2000 times for the outer loop. An approximation of the impact of screening was obtained by multiplying the incremental cost and QALYs of screening (per patient) by the number of individuals eligible for screening.
Determining the most cost-effective screening population

The point estimate ICER is <£30,000/QALY for 50-year-old men and <£20,000/QALY for 60-year-old men (Table 2). The ICER is >£30,000/QALY for women of all ages, however the most favourable ICER is observed for 60-year-old women. Therefore, age 60 years (males and females) was chosen as the base case for all subsequent analyses.

Analysis of uncertainty

For 60-year-old males, there is a 62% probability that the ICER is <£20,000/QALY and a 66% probability that the ICER is <£30,000/QALY. For 60-year-old females, there is a 44% probability that the ICER is <£20,000/QALY and a 56% probability that the ICER is <£30,000/QALY (Supplemental Figure 8).

Sensitivity analyses

Cost-effectiveness improves as the prevalence increases and the cost of ultrasound decreases (Table 3). Using £37[€47] as the cost of ultrasound, the ICER remains <£30,000/QALY so long as the prevalence of RCC is ≥0.25% for men and ≥0.2% for women aged 60 years. Using our current estimates for the prevalence of RCC for 60-year-old women, the ICER is <£30,000/QALY if the cost of screening ultrasound was reduced from £37 to ≤£30[€47 to ≤€38].
For 60-year-old males, the ICER remains £30,000/QALY so long as the disutility associated with screening is ≤0.05 for one week (Supplemental Table 6). The ICER is <£30,000/QALY, if the specificity of ultrasound is ≥85% (Supplemental Table 7). Furthermore, in the base case, it was assumed that the combined prevalence of incidental benign conditions detected by screening would be 2.7% [11, 17, 18]. The sensitivity analysis demonstrated that in 60-year-old men, the ICER remains <£30,000/QALY so long as the combined prevalence of other incidentally detected renal conditions is ≤20% (Supplemental Table 8). Sensitivity analyses for 60-year-old females are available in Supplemental Tables 6-8.

Value of information analysis

The number of individuals aged 60 years eligible to receive screening in the UK is 362,766 men/annum and 374,008 women/annum. Assuming a time horizon for which additional information is useful of ten years, this equates to a population that may benefit from screening of 3,122,576 men and 3,219,344 women (discounted at 3.5%) [36]. Given a willingness to pay threshold of £30,000/QALY, the population EVPI is £244,415,131 (€209,133,931) and £97,263,108 (€122,804,400) for 60-year-old males and females respectively (Supplemental Figure 9). The three parameters with the highest population EVPPI are the prevalence of RCC, the stage distribution of screen detected disease and the stage distribution of false negatives at screening (Figure 2).
Impact on health services

Compared with no screening, screening 60-year-old males results in an overall expected incremental cost per patient of £44.55 (cost of screening and treatment, discounted to present value) over a 30-year lifetime [€56]. The number of males eligible to receive screening in the UK is 362,766 per annum. Therefore, the present-value cost to the health service would be £16 million [€20 million] per cohort screened, over 30 years. However, the majority of screening costs are accrued up front when screening occurs. The expected incremental QALYs per patient is 0.0025 over 30 years (discounted to present value). Therefore, that equates to 893 QALYs gained per cohort screened. For 60-year-old women, screening would cost £17 million [€21 million] and would lead to 467 additional QALYs per cohort screened, over 30 years.
Discussion

Screening for RCC has the potential to improve survival outcomes[4, 5]. However, as with any screening program, there is also a potential for harm, including over-diagnosis, as well as psychological and economic implications for patients and society. No RCTs of screening for RCC have been undertaken[8]. We demonstrate that the population EVPI is £194 million and £97 million for 60-year-old men and women respectively. This suggests further research is likely to be of good value to the funder, and should be focused on estimating the prevalence of RCC and the stage shift associated with screening.

Determinants of cost-effectiveness

Using current evidence, this decision model suggests screening may be cost-effective in males but not females, due to lower prevalence of RCC in the latter[11, 14]. The true prevalence of RCC by age/sex in the UK is unknown. Sensitivity analysis suggests that screening may be cost-effective if the prevalence is ≥0.25% for males and ≥0.2% for females. A meta-analysis demonstrated the prevalence of RCC detected in middle-aged Americans undergoing screening CT is 0.21%[24]. Once again, the prevalence was not reported by age/sex, however it may indeed be above the threshold identified by our sensitivity analysis. Although beyond the scope of the present analysis, risk-stratified screening may increase cost-effectiveness by targeting screening towards individuals with a higher prevalence. At present there is a lack of specific, validated models to predict the risk of RCC and further research is required to elucidate this[8, 37]. Similarly, screening for AAA has been deemed cost-effective in men and not women, as the latter have a lower
prevalence of the disease[28, 38]. However, there are important equity considerations associated with screening only one sex[39].

The cost of screening ultrasound is a modifiable factor which is a major determinant of cost-effectiveness. Screening 60-year-old males remains cost-effective so long as the cost of ultrasound is <£60. This is very likely as it is below the current cost of ultrasound performed by a sonographer in secondary care[26]. When screening 60y females, the ICER drops <£30,000/QALY when the cost of ultrasound is reduced from £37 to £30. It is unclear whether the cost of technician-performed ultrasound may be reduced to this level. Renal ultrasound is technically more challenging to perform than aortic ultrasound. Accuracy is dependent on the size of the renal lesion and operator experience[40-42]. Our model suggests screening 60-year-old males remains cost-effective (i.e. ICER< £30,000) so long as the specificity of ultrasound is ≥85%, and the prevalence of benign incidental findings at ultrasound is ≤20%. All these conditions seem likely.

### Potential harms of screening

Evidence on the impact of screening for RCC on QoL is lacking[8, 22]. In the base case, it was assumed that undergoing screening ultrasound was not associated with a disutility, and this may contribute to the results demonstrating that the EVPPI for utilities was £0. However, in the sensitivity analysis, we showed that for 60-year-old men if the disutility associated with screening renal ultrasound is ≥0.05 for one week, screening is no longer cost-effective. This is because a small reduction in utility would be applied to such a large number of individuals receiving screening that it would outweigh any benefit to the small minority of patients in
which RCC is detected. Therefore, it is essential that any future RCC screening studies evaluate the impact of screening on QoL.

Strengths and limitations

A strength of this work is that it is the first decision analysis of screening for RCC in asymptomatic individuals. The model was designed with input from a multidisciplinary team of RCC experts and a patient advocate. Importantly, the model incorporates the impact of incidental findings detected by screening on cost-effectiveness. Systematic reviews were undertaken to determine key model inputs and where data were not available, structured expert elicitation was performed[8, 11, 22, 23]. This ensures that uncertainty surrounding parameter estimates was captured accurately, enabling reliable VOI[35].

The model represents a simplification of reality and shares some limitations inherent to all CEAs. Due to structural assumptions within the model, it was not appropriate to assess the impact of ultrasound sensitivity on the ICER, as the stage distribution of false positives was determined by evidence from the literature. Some CEAs in other disease areas have overcome this by modelling the natural history of undiagnosed disease[32]. However, there are no existing data on the transition probabilities between undiagnosed RCC stages. As there are eleven potential health states (diagnosed and undiagnosed stage I T1a, I T1b, II, III, IV, death) this would require 20 transition probabilities to be derived through expert elicitation. This would introduce undue uncertainty in the decision analysis, therefore it was felt that the current structure was the most appropriate. High profile CEAs in other disease areas, such as screening for breast cancer, have also chosen to develop less complex models
to minimize the assumptions and uncertainties arising from lack of data[43]. Life table models and discrete event simulation models of screening for breast cancer have achieved similar results[43, 44].

The CEA is limited by the absence of trial level data regarding certain model inputs. Conversely, a major indication for the CEA was to determine if undertaking a trial of screening was warranted on economic grounds. The prevalence of RCC was reported for a limited number of age groups[11, 14]. It was not possible to evaluate repeated screening at regular intervals, as screening studies scanned individuals only once. The model assumes that cancer-specific mortality is determined by RCC stage and is the same in the screening and no screening cohorts. Individuals with incidentally detected tumours have significantly better survival compared to symptomatic patients, after adjusting for tumour grade and stage[45]. Therefore, the model may underestimate the benefit of screening[46, 47]. However, as there are no RCTs demonstrating the effectiveness of screening, we do not know if screening in a contemporary population would lead to a stage shift nor whether it would impact survival. This consideration is particularly important as the number of individuals undergoing abdominal imaging for other indications is rising[48]. Further trial level data are required to quantify overdiagnosis and lead time bias. Additionally, there were few data on the prevalence of benign incidental findings at screening, and their associated impact on QoL or cost. We assigned a cost but no gain or loss of QALYs from incidental findings. This simplification may underestimate the cost-effectiveness of screening.
Conclusion

Given the available evidence and the current willingness to pay threshold, our model suggests that screening may be cost-effective in 60-year-old males. The prevalence of RCC by age/sex is a major determinant of cost-effectiveness and represents a key research priority, along with the stage shift associated with screening. Future work should focus on evaluating the potential harms of screening including the impact on QoL, incidental findings and overdiagnosis.
Figure 1: Structure of the Markov model

Figure 1 represents a simplified schematic of the Markov models; further details can be found in the Supplement. In brief, individuals without RCC can have a number of benign incidental findings (asymptomatic calculi, hydronephrosis etc). Individuals with RCC can be undiagnosed or diagnosed, by one of two ways: diagnosed via screening or opportunistically within the health service. Once RCC is diagnosed, individuals can be classified into one of the following five RCC health states: stage I T1a, stage I T1b, stage II, stage III and stage IV based on established AJCC staging criteria. Newly diagnosed (ND) health states are tunnel states reflecting costs and QALYs associated with the first year of diagnosis and treatment of RCC, with follow up costs accrued and discounted up front, as previously described [49]. These tunnel states will transition into long-term health states, which represent metastasis free (MF) states. Individuals will remain in each of these MF states until they progress (i.e. metastatic progression). Stage IV disease (shown in the dotted box) encompasses both newly diagnosed stage IV and metastatic recurrence. Stage IV disease may be subdivided into one of the following health states based on treatment: individuals with no progression (NP) on first line systemic therapy (“Stage IV, NP 1st line ST”) and those with who do not receive systemic therapy (“Stage IV, no ST”). These can lead to no progression on second line therapy (“Stage IV, NP 2nd line ST”), no progression on third line therapy (“Stage IV, NP 3rd line ST”), or progressive disease (“Stage IV, PD”). All health states can lead to “non RCC death” (i.e. background mortality) or “RCC death” via the “Terminal” tunnel health state, representing costs associated with the final year of life [49]. Arrows to these death health states are not shown to maintain clarity in the diagram.
Figure 1

Nodes:
- Simple Cyst
- Calculi
- Hydronephrosis
- Congenital anomaly
- RCC detected by health service
- RCC detected by screening
- ND Stage I T1a
- ND Stage I T1b
- ND Stage II
- ND Stage III
- MF Stage I T1a
- MF Stage I T1b
- MF Stage II
- MF Stage III
- Stage IV
- NP 1st line therapy
- NP 2nd line therapy
- NP 3rd line therapy
- Stage IV PD
- Stage IV No ST
- Non RCC Death
- Terminal
- RCC death

Connections:
- RCC detected by health service -> ND Stage I T1a -> MF Stage I T1a
- RCC detected by health service -> ND Stage I T1b -> MF Stage I T1b
- RCC detected by health service -> ND Stage II -> MF Stage II
- RCC detected by health service -> ND Stage III -> MF Stage III
- ND Stage I T1a -> Stage IV
- ND Stage I T1b -> Stage IV
- ND Stage II -> Stage IV
- ND Stage III -> Stage IV
- MF Stage I T1a -> NP 1st line therapy
- MF Stage I T1b -> NP 2nd line therapy
- MF Stage II -> NP 3rd line therapy
- Stage IV PD -> NP 1st line therapy
- Stage IV PD -> NP 2nd line therapy
- Stage IV PD -> NP 3rd line therapy
- Stage IV No ST -> NP 3rd line therapy

End points:
- Non RCC Death
- Terminal
- RCC death
The population expected value of perfect parameter information (EVPPI) at a willingness to pay threshold of £30,000/QALY is shown for males and females aged 60 years. The parameters investigated were: screening parameters, costs, utilities, transition probabilities (TP) and stage distribution (SD) i.e. the proportion of individuals with RCC in each cancer stage. The “% receiving each therapy” refers to the proportion of individuals with RCC who undergo each management option, for example, ablation, active surveillance, surgery (open vs laparoscopic, partial vs radical) etc. “Utilities” refers to all utilities in the model, not just the utility associated with screening. Note, the EVPPIs do not sum to the EVPI due to parameter correlation.
Tables

Table 1: Model inputs

For each model input, the mean estimate along with the 95% confidence interval (CI) or standard error (SE) is shown. For costs, the interquartile range (IQR) is reported as this is the data provided by the national schedule of referencing costs. Parameters of the distribution used in the probabilistic sensitivity analysis are demonstrated. For parameters derived through expert elicitation, the median estimate and 95% credibility intervals (CrI) are shown. For modified Connor Mosimann distributions (mCM), the a, b, L, U parameters are shown. Medians do not sum to 1, however means do (data not shown). The ordering of Zed parameters is critical to ensure correct calculation of probabilities, although this order may not be the same as the logical order (stages I-IV). Further details regarding how transition probabilities and summary costs were derived are available in the Supplement.

| Parameter | Source | Mean (95% CI) | Distribution |
|-----------|--------|---------------|--------------|
| **Screening parameters** | | | | |
| Sensitivity of ultrasound | [16, 17, 50, 51] | 81.8% (52.3%-94.9%) | Beta (9,2) |
| Specificity of ultrasound | [16, 17] | 98.2% (97.9%-98.5%) | Beta (9771, 177) |
| Specificity of CT following a positive ultrasound | [17] | 98.9% (96.0%-99.7%) | Beta (175,2) |
| Prevalence of asymptomatic hydronephrosis | [11] | 0.48% (0.21-0.87%) | Beta (8.05, 1654.60) |
| Prevalence of asymptomatic stones | [11] | 1.82% (0.59-3.64%) | Beta (5.03, 275.51) |
| Prevalence of other benign asymptomatic findings on screening^~ | [17, 18] | 0.40% (0.30%-0.55%) | Beta (40, 9919) |

**Prevalence of RCC**

| Parameter | Source | Mean (95% CI) | Distribution |
|-----------|--------|---------------|--------------|
| Prevalence in 40-year-old males | | 0.14% (0.08-0.23%) | Beta (14.24, 9780.69) |
| Prevalence in 50-year-old males | | 0.23% (0.12-0.37%) | Beta (12.58, 5502.85) |
| Prevalence in 60-year-old males | Adapted from [11, 14, 25] | 0.34% (0.18-0.54%) | Beta (13.17, 3905.89) |
| Prevalence in 40-year-old females | | 0.07% (0.04-0.11%) | Beta (15.49, 21892.72) |
| Prevalence in 50-year-old females | | 0.09% (0.05-0.14%) | Beta (14.97, 16729.45) |
| Prevalence in 60-year-old females | | 0.16% (0.08-0.25%) | Beta (12.30, 8011.51) |

**Stage distribution**

| Parameter | Source | Mean (95% CI or 95% CrI) | Distribution |
|-----------|--------|-----------------|--------------|

Screen detected RCC

| Stage          | Probability | Distribution          |
|----------------|-------------|-----------------------|
| Stage I T1a    | 45.45% (34.0%-57.4%) | Dirichlet (30, 27, 9) |
| Stage I T1b    | 40.91% (29.9%-53.0%)   | Dirichlet (30, 27, 9) |
| Stage II       | 13.64% (7.3%-23.9%)    | Dirichlet (173, 28.4) |
| Stages I-II    | 84.39% (78.8%-88.7%)   | Dirichlet (173, 28.4) |
| Stage III      | 13.66% (9.6%-19.0%)    | Dirichlet (173, 28.4) |
| Stage IV       | 1.95% (0.8%-4.9%)      | Dirichlet (173, 28.4) |

RCC detected by the health service

| Stage          | Probability | Distribution          |
|----------------|-------------|-----------------------|
| Stage I T1a    | 55.58% (54.1%-57.0%) | Beta (2007, 2511)  |
| Stage I T1b    | 44.42% (44.0%-45.9%)  | Beta (2007, 2511)  |
| Stage I        | 44.21% (42.96%-45.46%) | Dirichlet (2678,578,1116,1686) |
| Stage II       | 9.54% (8.83%-10.31%)  | Dirichlet (2678,578,1116,1686) |
| Stage III      | 18.42% (17.47%-19.42%) | Dirichlet (2678,578,1116,1686) |
| Stage IV       | 27.83% (26.72%-28.97%) | Dirichlet (2678,578,1116,1686) |

Stage distribution of false positives

| Stage          | Probability | Distribution          |
|----------------|-------------|-----------------------|
| Stage I T1a    | 60.7% (57.1%-64.1%) | Dirichlet (451, 168, 124) |
| Stage I T1b    | 22.6% (19.7%-25.8%)  | Dirichlet (451, 168, 124) |
| Stages II      | 16.7% (14.2%-19.5%)  | Dirichlet (451, 168, 124) |
| Stage III      | 0%           | Dirichlet (451, 168, 124) |
| Stage IV       | 0%           | Dirichlet (451, 168, 124) |

False negatives at screening

| Stage          | Probability | Distribution          |
|----------------|-------------|-----------------------|
| Stage I T1a    | 76% (43%-95%) | mCM (6.72, 2.41, 0, 1) |
| Stage I T1b    | 9% (1%-44%)  | mCM (0.35, 0.49, 0.157, 1) |
| Stage IV       | 4% (0%-32%)  | mCM (0.64, 0.40, 0, 1) |
| Stage II       | 1% (0%-14%)  | mCM (10, 10, 0, 1) |
| Stage III      | 1% (0%-14%)  | mCM (10, 10, 0, 1) |

Annual transition probabilities

| Parameter | Source | Mean (95% CI) | Distribution |
|-----------|--------|---------------|--------------|

**Stage I T1a**

- Stage I T1a > Stage I T1a: 1-sum of other probabilities
- Stage I T1a > Stage IV: 0.0110 (0.00552, 0.0183) | Beta (11.04, 991.96)
- Stage I T1a > RCC death: 0.00424 (0.00346, 0.00509) | Beta (102.80, 24165.20)

**Stage I T1b**

- Stage I T1b > Stage I T1b: 1-sum of other probabilities
- Stage I T1b > Stage IV: 0.0326 (0.0216-0.0457) | Beta (26.91, 799.11)
- Stage I T1b > RCC death: 0.0198 (0.0178-0.0219) | Beta (349.31, 17322.70)

**Stage II**

- Stage II > Stage II: 1-sum of other probabilities
- Stage II > Stage IV: 0.0538 (0.0371, 0.0733) | Beta (31.85, 560.15)
- Stage II > RCC death: 0.0306 (0.0131-0.0544)** | Beta (7.86, 250.99)

**Stage III**

- Stage III > Stage III: 1-sum of other probabilities
- Stage III > Stage IV: 0.104 (0.0810, 0.129) | Beta (64.69, 559.31)
- Stage III > RCC death: 0.105 (0.0828-0.131)** | Beta (64.88, 547.54)
No progression (NP) on 1\textsuperscript{st} line therapy

| Event                                | Proportion     | Distribution                  |
|--------------------------------------|----------------|-------------------------------|
| NP on 1\textsuperscript{st} line therapy > NP on 1\textsuperscript{st} line therapy | 0.274 (0.242-0.307) | Dirichlet (201, 181, 351) |
| NP on 1\textsuperscript{st} line therapy > progressive disease | 0.247 (0.216-0.278) | baseline                     |
| NP on 1\textsuperscript{st} line therapy > death | 0.479 (0.443-0.515) | baseline                     |

No progression (NP) on 2\textsuperscript{nd} line therapy

| Event                                | Proportion     | Distribution                  |
|--------------------------------------|----------------|-------------------------------|
| NP on 2\textsuperscript{nd} line therapy > NP on 2\textsuperscript{nd} line therapy | 0.186 (0.162-0.211) | Beta (177.04, 775.96) |
| NP on 1\textsuperscript{st} line therapy > progressive disease | 1-sum of other probabilities | baseline                     |
| NP on 1\textsuperscript{st} line therapy > death | 0.595 (0.577-0.613) | Beta (1739.46, 1182.54) |

No progression (NP) on 3\textsuperscript{rd} line therapy

| Event                                | Proportion     | Distribution                  |
|--------------------------------------|----------------|-------------------------------|
| NP on 3\textsuperscript{rd} line therapy > NP on 3\textsuperscript{rd} line therapy | 1-sum of other probabilities | baseline                     |
| NP on 3\textsuperscript{rd} line therapy > progressive disease | 0.451 (0.420-0.482) | Beta (447.56, 545.44) |
| NP on 3\textsuperscript{rd} line therapy > death | 0.489 (0.458-0.520) | Beta (485.27, 507.73) |

Stage IV, No systemic therapy

| Event                                | Proportion     | Distribution                  |
|--------------------------------------|----------------|-------------------------------|
| No systemic therapy > death | 0.646 (0.616-0.677) | Beta (605.07, 330.93) |

Progressive Disease (PD)

| Event                                | Proportion     | Distribution                  |
|--------------------------------------|----------------|-------------------------------|
| PD > PD                             | 0.908 (0.797-0.977) | Beta (33.58, 3.42) |
| PD > death | 0.25 (0.01-0.76) | Beta (1.07, 2.65) |

Undiagnosed > Diagnosed RCC

| Event                                | Proportion     | Distribution                  |
|--------------------------------------|----------------|-------------------------------|
| Opportunistic detection by health service | 0.024 (77/3158) | Beta (77, 3081) |

Proportion undergoing each management option

| Management option | Source | Proportion (n/N) | Distribution                  |
|------------------|--------|-----------------|-------------------------------|
| Stage I RCC (T1a) |        |                 |                               |
| Active Surveillance | Expert opinion | 0.024 (77/3158) | Beta (77, 3081) |
| Percutaneous ablation | [66] | 0.145 (235/1617) | baseline                     |
| Open partial nephrectomy | [67] | 0.138 (223/1617) | baseline                     |
| Laparoscopic partial nephrectomy | [67] | 0.306 (494/1617) | Dirichlet (235, 223, 494, 52, 588, 25) |
| Robotic partial nephrectomy | [67] | 0.032 (52/1617) | baseline                     |
| Open radical nephrectomy | [67] | 0.364 (588/1617) | baseline                     |
| Laparoscopic radical nephrectomy | [67] | 0.015 (25/1617) | baseline                     |
| Robotic radical nephrectomy | [67] | 0.015 (25/1617) | baseline                     |

Stage I RCC (T1b)

| Management option | Proportion     | Distribution                  |
|------------------|----------------|-------------------------------|
| Open partial nephrectomy | [67] | 0.074 (108/1455) | baseline                     |
| Laparoscopic partial nephrectomy | [67] | 0.014 (21/1455) | baseline                     |
| Robotic partial nephrectomy | [67] | 0.056 (81/1455) | Dirichlet (108, 21, 81, 151, 1040, 54) |
| Open radical nephrectomy | [67] | 0.104 (151/1455) | baseline                     |
| Laparoscopic radical nephrectomy | [67] | 0.715 (1040/1455) | baseline                     |
| Robotic radical nephrectomy | [67] | 0.037 (54/1455) | baseline                     |

Stage II RCC

| Management option | Proportion     |
|------------------|----------------|
| Open partial nephrectomy | 0.019 (27/1419) |
| Procedure                                      | Reference | Proportion | Source                     | Distribution          |
|------------------------------------------------|-----------|------------|----------------------------|-----------------------|
| Laparoscopic partial nephrectomy               | [67]      | 0.003 (4/1419) | Dirichlet (27, 4, 16, 580, 766, 26) |
| Robotic partial nephrectomy                    | [67]      | 0.011 (16/1419) |                            |                       |
| Open radical nephrectomy                       | [67]      | 0.409 (580/1419) |                            |                       |
| Laparoscopic radical nephrectomy               | [67]      | 0.540 (766/1419) |                            |                       |
| Robotic radical nephrectomy                    | [67]      | 0.018 (26/1419)  |                            |                       |

### Stage III RCC

| Procedure                                      | Reference | Proportion | Source                     | Distribution          |
|------------------------------------------------|-----------|------------|----------------------------|-----------------------|
| Open radical nephrectomy                       |           | 0.51       | Uniform (0.35, 0.65)       |                       |
| Laparoscopic or robotic radical nephrectomy    |           | 0.49       | Uniform (0.65, 0.35)       |                       |

### Stage IV RCC

| Procedure                                      | Reference | Proportion | Source                     | Distribution          |
|------------------------------------------------|-----------|------------|----------------------------|-----------------------|
| Cytoreductive nephrectomy                      | [68-74]   | 0.37 (18,831/50,895) | Beta (18831, 32064)       |                       |
| Metastasectomy                                 | [57, 75]  | 0.17 (107/623)  | Beta (107, 516)            |                       |
| Palliative radiotherapy for bone pain          | [76, 77]  | 0.12 (137/1108) | Beta (137, 971)            |                       |
| Proportion of patients receiving no systemic therapy | [63, 78-83] | 0.28 (104/365) | Beta (104, 261)           |                       |
| Proportion receiving first line therapy        | [83]      | 0.72 (261/365)  | Beta (261, 104)            |                       |
| Proportion of individuals on first line therapy who receive sunitinib | [84]      | 0.43 (527/1229) | Beta (527, 702)           |                       |
| Proportion of individuals on first line therapy who receive second line therapy | [83]      | 0.47 (123/261)  | Beta (123, 138)           |                       |
| Proportion of individuals on second line therapy who receive third line therapy | [83]      | 0.33 (41/123)   | Beta (41, 82)             |                       |

### Unit costs

| Parameter | Source | Mean (SE) or (IQR) | Distribution |
|-----------|--------|-------------------|--------------|
| Screening costs |        |                   |              |
| Invitation (clerical staff time, postage and stationery, cost of obtaining patient details, office space and equipment) | [21]  | £1.94 (€2) (0.49) | Gamma (16, 0.12) |
| Technician performed ultrasound | [21]  | £37.53 (€47) (9.38) | Gamma (16, 2.35) |
| CT Abdomen & Pelvis with contrast | [26]  | £115 (€145) (€88-€134) | Gamma (10.59, 10.66) |
| Assessment |        |                   |              |
| Clinical biochemistry | [26]  | £1 (€1) (€1-€1) | Constant |
| Haematology | [26]  | £3 (€4) (€2-€4) | Gamma (4.08, 0.77) |
| Phlebotomy | [26]  | £3 (€4) (€2-€4) | Gamma (4.08, 0.77) |
| Histopathology | [26]  | £31 (€39) (€15-€36) | Gamma (2.66, 10.25) |
| CT chest with contrast | [26]  | £102 (€129) (€71-€135) | Gamma (4.70, 22.77) |
| CT of three areas with contrast | [26]  | £121 (€153) (€88-€139) | Gamma (9.01, 12.86) |
| CT brain | [26]  | 102 (€129) (€71-€135) | Gamma (4.70, 22.77) |
| Outpatient renal biopsy | [26]  | £158 (€199) (€125-€194) | Gamma (9.72, 16.72) |
| Urology outpatient clinic | [26]  | £105.19 (€133) (10.52) | Gamma (100, 1.05) |
| Oncology clinic | [26]  | £151 (€191) (€125-€194) | Gamma (9.72, 16.72) |
| MDT discussion | [26]  | £107 (€135) (€71-€131) | Gamma (5.15, 20.33) |
## Management

| Procedure                                      | Cost (2020 £/€)                     | Distribution (95%CI)                     |
|------------------------------------------------|-------------------------------------|-----------------------------------------|
| Percutaneous Cryoablation                      | £5,372 [€6,783]                     | Gamma (4.67, 1113.35)                   |
| Percutaneous, Microwave or Radiofrequency Ablation | £2,952 [€3,727]                     | Gamma (3.66, 756.08)                   |
| Laparoscopic nephrectomy (partial or radical)  | £6,581 [€8,309]                     | Gamma (62.33, 105.59)                  |
| Open nephrectomy (partial or radical)          | £8,021 [€10,127]                    | Gamma (30.55, 262.55)                  |
| Robotic nephrectomy (partial or radical)       | £6,534 [€8,250]                     | Gamma (65.32, 100.03)                  |
| Cytoreductive nephrectomy                       | £9,938 [€12,548]                    | Gamma (100, 99.38)                     |
| Metastasectomy for thoracic metastases        | £6,514 [€8,225]                     | Gamma (10.08, 637.65)                  |
| Metastasectomy for abdominal metastases       | £4,101 [€5,178]                     | Gamma (3.57, 1160.30)                  |
| Radiotherapy (preparation and delivery)        | £388 [€490]                         | Gamma (6.34, 61.79)                    |

## Annual drug costs

| Drug               | Cost (2020 £/€)                     | Distribution (95%CI)                     |
|--------------------|-------------------------------------|-----------------------------------------|
| Sunitinib          | £16,120 [€20,353]                   | Constant                                |
| Pazopanib          | £16,304 [€20,585]                   | Constant                                |
| Everolimus         | £25,765 [€32,531]                   | Constant                                |
| Axitinib           | £29,543 [€37,301]                   | Constant                                |
| Cabozantinib       | £54,002 [€68,183]                   | Constant                                |
| Nivolumab          | £57,625 [€72,757]                   | Constant                                |
| Lenvatinib & Everolimus | £51,668 [€65,236]     | Constant                                |

## Summary costs for health states

| Health State                                | Cost (2020 £/€)                | Distribution (95%CI)                     |
|---------------------------------------------|--------------------------------|-----------------------------------------|
| Incidental hydronephrosis or renal stone    | £220 [€278]                    | Constant                                |
| Incidental congenital renal anomaly         | £105 [€133]                    | £7,510 [€9,482]                         |
| Newly diagnosed Stage I T1a                 | £6,821 [€8,612]                |                                        |
| Newly diagnosed Stage I T1b                 |                                  |                                        |
Newly diagnosed Stage II £8,110 [€10,240]
Newly diagnosed Stage III £8,595 [€10,852]
Metastasis free Stage I-III £0
Undiagnosed RCC £0
False positive (<4cm) £6,889 [€8,698]
False positive (4-7cm) £7,259 [€9,165]
False positive (>7cm) £7,622 [€9,624]
Newly diagnosed stage IV £4,555 [€5,751]
Newly diagnosed metastatic recurrence £759 [€958]
No progression on 1st line ST £19,244 [€24,297]
No progression on 2nd line ST £47,041 [€59,394]
No progression on 3rd line ST £47,041 [€59,394]
Stage IV, no systemic therapy [77, 81] £1,428 [€1,803]
Progressive disease [77, 81] £1,690 [€2,134]
Terminal care costs [92] £11,616 [€14,666]

Utilities

| Parameter                  | Source | Mean | Distribution |
|----------------------------|--------|------|--------------|
| Screening Ultrasound       | Assumption | Varied in sensitivity analysis | Constant |
| No cancer                  | Assumption | 1 | Constant |
| Undiagnosed Cancer         | Assumption | 1 | Constant |
| Newly diagnosed Stage I T1a | Clinical expert | 0.934 (5) | Beta (5.64, 0.40) |
| Newly diagnosed Stage I T1b | Clinical expert | 0.934 (5) | Beta (5.64, 0.40) |
| Newly diagnosed Stage II    | Clinical expert | 0.869 (8) | Beta (12.28, 1.86) |
| Newly diagnosed Stage III   | Clinical expert | 0.869 (8) | Beta (12.28, 1.86) |
| Metastasis free Stages I-III|       | 1 | Constant |
| False positive Stage I T1a | Assumption | 0.934 (5) | Beta (5.64, 0.40) |
| False positive Stage I T1b | Assumption | 0.934 (5) | Beta (5.64, 0.40) |
| False positive Stage II     | Assumption | 0.869 (8) | Beta (12.28, 1.86) |
| Stage IV, NP on 1st line therapy | [94-98] | 0.78 | Beta (1337.7, 377.3) |
| Stage IV, NP on 2nd line therapy | [77] | 0.70 | Beta (29.3, 12.56) |
| Stage IV, NP on 3rd line therapy | Assumption based on [77] | 0.70 | Beta (29.3, 12.56) |
| Stage IV, NST               | [77] | 0.69 | Beta (500.31, 222.68) |
| Progressive Disease         | [77] | 0.61 | Beta (441.03, 281.97) |
| Terminal, RCC Death and Non-RCC Death | Assumption | 0 | Constant |

*Small or atrophic kidneys, aplasia, dysplasia, duplication or horseshoe kidney

*Proportions of those stage I-II
**Proportions of stage I**

**Relative survival, therefore this was converted to absolute survival using the age dependent probability of background mortality (see Supplement for details).**

Overall survival data was utilised to calculate the transition probability from each health state to death. This value was subsequently adjusted based on known age dependent background mortality to derive the transition probability for RCC death.

It was assumed 28.8% (17/59) of individuals undergo surgical management for thoracic metastases and 71.2% (42/59) for abdominal metastases [75].

**Equivalent to a utility of 0.737 for 3 months and a utility of 1 for 9 months**

**Equivalent to a utility of 0.737 for 6 months and a utility of 1 for 6 months**
### Table 2: Baseline results

The incremental costs (cost of screening and treatment), quality adjusted life years (QALYs) and incremental cost-effectiveness ratio (ICER) per person screened is shown for each age and sex.

| Males   | Females   |
|---------|-----------|
|         | 40 years  | 50 years  | 60 years  | 40 years  | 50 years  | 60 years  |
| Prevalence of RCC | 0.14% (0.08-0.23%) | 0.23% (0.12-0.37%) | 0.34% (0.18-0.54%) | 0.07% (0.04-0.11%) | 0.09% (0.05-0.14%) | 0.16% (0.08-0.25%) |
| Incremental costs | £47.06 | £45.69 | £44.55 | £47.61 | £46.99 | £46.56 |
| Incremental QALYs | 0.00155 | 0.00205 | 0.00246 | 0.000809 | 0.000937 | 0.00125 |
| ICER    | £30,367 | £22,277 | £18,092 | £58,819 | £50,160 | £37,327 |
Table 3: Results of the two-way sensitivity analysis of age, sex, prevalence of RCC and cost of screening ultrasound

The incremental cost-effectiveness ratio (ICER) is shown for each age and sex. Values are highlighted in green if the ICER < £20,000/QALY, amber if the ICER £20,000-£30,000/QALY and red if the ICER > £30,000/QALY.

| Prevalence | Males | | | | Females | | | |
|------------|--|---|---|---|---|---|---|---|
|             | 40 years | 50 years | 60 years | 40 years | 50 years | 60 years | 40 years | 50 years | 60 years |
| 0.0005      | £79,384 | £99,763 | £134,251 | £77,526 | £93,379 | £123,795 |
| 0.001       | £41,969 | £49,599 | £69,003 | £38,733 | £44,318 | £57,667 |
| 0.0015      | £30,359 | £31,496 | £46,545 | £25,266 | £28,901 | £37,799 |
| 0.002       | £20,832 | £25,143 | £33,320 | £18,935 | £22,306 | £29,603 |
| 0.0025      | £14,949 | £18,784 | £26,377 | £14,592 | £18,170 | £22,058 |
| 0.003       | £12,969 | £15,546 | £21,163 | £12,212 | £14,615 | £19,429 |
| 0.0035      | £9,961  | £12,046 | £16,676 | £10,474 | £12,308 | £15,710 |
| 0.004       | £9,154  | £11,830 | £15,644 | £8,920  | £10,399 | £13,846 |
| 0.0045      | £7,803  | £9,990  | £14,633 | £7,533  | £8,897  | £11,548 |
| 0.005       | £6,862  | £8,433  | £12,774 | £6,611  | £7,957  | £10,285 |
| 0.0055      | £6,209  | £8,232  | £11,438 | £6,152  | £7,413  | £9,151  |
| 0.006       | £5,651  | £7,786  | £10,123 | £5,716  | £6,863  | £8,862  |

Cost of US

| Cost of US | | | | | | | | |
|------------|--|---|---|---|---|---|---|---|
| £70        | £47,863 | £34,319 | £34,000 | £91,772 | £85,491 | £69,092 |
| £60        | £40,587 | £31,717 | £29,317 | £81,603 | £76,915 | £59,227 |
| £50        | £35,309 | £26,187 | £24,134 | £68,069 | £62,299 | £45,981 |
| £40        | £29,199 | £21,161 | £18,443 | £57,431 | £52,414 | £38,759 |
| £30        | £23,165 | £18,479 | £16,061 | £45,740 | £42,234 | £28,754 |
| £20        | £16,371 | £13,141 | £11,340 | £37,756 | £34,387 | £23,083 |
References

[1] Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gulmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383:156-65.

[2] Hassan C, Hunink MG, Laghi A, Pickhardt PJ, Zullo A, Kim DH, et al. Value-of-information analysis to guide future research in colorectal cancer screening. Radiology. 2009;253:745-52.

[3] Motzer RJ. Perspective: What next for treatment? Nature. 2016;537:S111.

[4] Jones J, Bhatt J, Avery J, Laupacis A, Cowan K, Basappa N, et al. The kidney cancer research priority-setting partnership: Identifying the top 10 research priorities as defined by patients, caregivers, and expert clinicians. Can Urol Assoc J. 2017;11:379-87.

[5] The Kidney Cancer UK patient survey report 2018. In: UK KC, editor.2018.

[6] Rossi SH, Blick C, Handforth C, Brown JE, Stewart GD, Renal Cancer Gap Analysis C. Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement. Eur Urol Focus. 2019.

[7] Five-Year Relative Survival by Stage, Adults (Aged 15-99 Years), Former Anglia Cancer Network, 2002-2006. Cancer Research UK; 2014.

[8] Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol. 2018;36:1341-53.

[9] Darwood R, Earnshaw JJ, Turton G, Shaw E, Whyman M, Poskitt K, et al. Twenty-year review of abdominal aortic aneurysm screening in men in the county of Gloucestershire, United Kingdom. J Vasc Surg. 2012;56:8-13.
[10] Wanhainen A, Hultgren R, Linne A, Holst J, Gottsater A, Langenskiold M, et al. Outcome of the Swedish Nationwide Abdominal Aortic Aneurysm Screening Program. Circulation. 2016;134:1141-8.

[11] Rossi SH, Hsu R, Blick C, Goh V, Nathan P, Nicol D, et al. Meta-analysis of the prevalence of renal cancer detected by abdominal ultrasonography. Br J Surg. 2017;104:648-59.

[12] Spouge AR, Wilson SR, Wooley B. Abdominal sonography in asymptomatic executives: prevalence of pathologic findings, potential benefits, and problems. J Ultrasound Med. 1996;15:763-7; quiz 9-70.

[13] Fujii Y, Ajima J, Oka K, Tosaka A, Takehara Y. Benign renal tumors detected among healthy adults by abdominal ultrasonography. Eur Urol. 1995;27:124-7.

[14] Mihara S, Kuroda K, Yoshioka R, Koyama W. Early detection of renal cell carcinoma by ultrasonographic screening--based on the results of 13 years screening in Japan. Ultrasound Med Biol. 1999;25:1033-9.

[15] Tsuboi N, Horiuchi K, Kimura G, Kondoh Y, Yoshida K, Nishimura T, et al. Renal masses detected by general health checkup. Int J Urol. 2000;7:404-8.

[16] Mizuma Y, Watanabe Y, Ozasa K, Hayashi K, Kawai K. Validity of sonographic screening for the detection of abdominal cancers. J Clin Ultrasound. 2002;30:408-15.

[17] Filipas D, Spix C, Schulz-Lampel D, Michaelis J, Hohenfellner R, Roth S, et al. Screening for renal cell carcinoma using ultrasonography: a feasibility study. BJU Int. 2003;91:595-9.

[18] Malaeb BS, Martin DJ, Littooy FN, Lotan Y, Waters WB, Flanigan RC, et al. The utility of screening renal ultrasonography: identifying renal cell carcinoma in an elderly asymptomatic population. BJU Int. 2005;95:977-81.

[19] NICE. National Institute for Health and Care Excellence Guide to the methods of technology appraisal. 2013.
352 [20] Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. Clin Ther. 2013;35:356-63.

353 [21] Thompson SG, Brown LC, Sweeting MJ, Bown MJ, Kim LG, Glover MJ, et al. Systematic review and meta-analysis of the growth and rupture rates of small abdominal aortic aneurysms: implications for surveillance intervals and their cost-effectiveness. Health Technol Assess. 2013;17:1-118.

354 [22] Rossi SH, Klatte T, Stewart GD. Quality of life outcomes in patients with localised renal cancer: a literature review. World J Urol. 2018.

355 [23] Rossi S.H. BC, Nicol D., Stewart G.D., Wilson E.C.F. Expert elicitation to inform a cost effectiveness analysis of screening for renal cancer. Value Health. 2019; In press.

356 [24] Fenton JJ, Weiss NS. Screening computed tomography: will it result in overdiagnosis of renal carcinoma? Cancer. 2004;100:986-90.

357 [25] Population Estimates for UK, England and Wales, Scotland and Northern Ireland: Mid-2017. In: Statistics OfN, editor. 2017.

358 [26] NHS reference costs 2015 to 2016. In: Care DoHaS, editor. 2016.

359 [27] Ashton HA, Buxton MJ, Day NE, Kim LG, Marteau TM, Scott RA, et al. The Multicentre Aneurysm Screening Study (MASS) into the effect of abdominal aortic aneurysm screening on mortality in men: a randomised controlled trial. Lancet. 2002;360:1531-9.

360 [28] Glover MJ, Kim LG, Sweeting MJ, Thompson SG, Buxton MJ. Cost-effectiveness of the National Health Service Abdominal Aortic Aneurysm Screening Programme in England. Br J Surg. 2014;101:976-82.

361 [29] Kim LG, Thompson SG, Briggs AH, Buxton MJ, Campbell HE. How cost-effective is screening for abdominal aortic aneurysms? J Med Screen. 2007;14:46-52.
[30] Barrett J, Jenkins V, Farewell V, Menon U, Jacobs I, Kilkerr J, et al. Psychological morbidity associated with ovarian cancer screening: results from more than 23,000 women in the randomised trial of ovarian cancer screening (UKCTOCS). BJOG. 2014;121:1071-9.

[31] Reade CJ, Riva JJ, Busse JW, Goldsmith CH, Elit L. Risks and benefits of screening asymptomatic women for ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013;130:674-81.

[32] Wilson ECF, Usher-Smith JA, Emery J, Corrie P, Walter FM. A Modeling Study of the Cost-Effectiveness of a Risk-Stratified Surveillance Program for Melanoma in the United Kingdom. Value Health. 2018;21:658-68.

[33] Briggs A, Claxton K., Sculpher M. Decision analytic modelling for health economic evaluation: Oxford University Press; 2011.

[34] Wilson E.C.F. AK. From evidence-based economics to economics-based evidence: using systematic review to inform the design of future research. In: Shemilt I, MM, Vale L., Marsh K., Donaldson C., editor. Evidence-Based Decisions and Economics Health care, social welfare, education and criminal justice: Blackwell Publishing Ltd.; 2010.

[35] Wilson E, Abrams K. From Evidence Based Economics to Economics Based Evidence: Using Systematic Review to inform the design of future research. In: Shemilt I, Mugford M, Vale L, Marsh K, Donaldson C, editors. Evidence Based Economics. London: Blackwell Publishing; 2010.

[36] Philips Z, Claxton K, Palmer S. The half-life of truth: what are appropriate time horizons for research decisions? Med Decis Making. 2008;28:287-99.

[37] Scelo G, Muller DC, Riboli E, Johannson M, Cross AJ, Vineis P, et al. KIM-1 as a blood-based marker for early detection of kidney cancer: a prospective nested case-control study. Clin Cancer Res. 2018.
[38] Sweeting MJ, Masconi KL, Jones E, Ulug P, Glover MJ, Michaels JA, et al. Analysis of clinical benefit, harms, and cost-effectiveness of screening women for abdominal aortic aneurysm. Lancet. 2018.

[39] Current UK National Screening Committee Recommendations. UK National Screening Committee 2016.

[40] Warshauer DM, McCarthy SM, Street L, Bookbinder MJ, Glickman MG, Richter J, et al. Detection of renal masses: sensitivities and specificities of excretory urography/linear tomography, US, and CT. Radiology. 1988;169:363-5.

[41] Jamis-Dow CA, Choyke PL, Jennings SB, Linehan WM, Thakore KN, Walther MM. Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology. 1996;198:785-8.

[42] Schmidt T, Hohl C, Haage P, Blaum M, Honnef D, Weibeta C, et al. Diagnostic accuracy of phase-inversion tissue harmonic imaging versus fundamental B-mode sonography in the evaluation of focal lesions of the kidney. AJR Am J Roentgenol. 2003;180:1639-47.

[43] Pashayan N, Morris S, Gilbert FJ, Pharoah PDP. Cost-effectiveness and Benefit-to-Harm Ratio of Risk-Stratified Screening for Breast Cancer: A Life-Table Model. JAMA Oncol. 2018.

[44] Gray E, Dotten A, Karssemeijer N, van Gils C, Evans DG, Astley S, et al. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis. Value Health. 2017;20:1100-9.

[45] Ficarra V, Prayer-Galetti T, Novella G, Bratti E, Maffei N, Dal Bianco M, et al. Incidental detection beyond pathological factors as prognostic predictor of renal cell carcinoma. Eur Urol. 2003;43:663-9.
Ficarra V, Schips L, Guille F, Li G, De La Taille A, Prayer Galetti T, et al. Multiinstitutional European validation of the 2002 TNM staging system in conventional and papillary localized renal cell carcinoma. Cancer. 2005;104:968-74.

Patard JJ, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Prognostic significance of the mode of detection in renal tumours. BJU Int. 2002;90:358-63.

Welch HG, Skinner JS, Schroeck FR, Zhou W, Black WC. Regional Variation of Computed Tomographic Imaging in the United States and the Risk of Nephrectomy. JAMA Intern Med. 2017.

Wilson EC, Emery JD, Kinmonth AL, Prevost AT, Morris HC, Humphrys E, et al. The cost-effectiveness of a novel SIAscopic diagnostic aid for the management of pigmented skin lesions in primary care: a decision-analytic model. Value Health. 2013;16:356-66.

Halpern JA, Chughtai B, Ghomrawi H. Cost-effectiveness of Common Diagnostic Approaches for Evaluation of Asymptomatic Microscopic Hematuria. JAMA Intern Med. 2017;177:800-7.

Corcoran AT, Russo P, Lowrance WT, Asnis-Alibozek A, Libertino JA, Pryma DA, et al. A review of contemporary data on surgically resected renal masses--benign or malignant? Urology. 2013;81:707-13.

Thorstenson A, Harmenberg U, Lindblad P, Holmstrom B, Lundstam S, Ljungberg B. Cancer Characteristics and Current Treatments of Patients with Renal Cell Carcinoma in Sweden. Biomed Res Int. 2015;2015:456040.

TNM stage group by CCG by tumour type for 10 tumour types, 2013. 3 ed: National Cancer Intelligence Network; 2013.

Violette P, Abourbih S, Szymanski KM, Tanguay S, Aprikian A, Matthews K, et al. Solitary solid renal mass: can we predict malignancy? BJU Int. 2012;110:E548-52.
[55] Thompson RH, Kurta JM, Kaag M, Tickoo SK, Kundu S, Katz D, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181:2033-6.

[56] Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170:2217-20.

[57] Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016;34:1081-6.

[58] Pierorazio PM, Johnson MH, Patel HD, Sozio SM, Sharma R, Iyoha E, et al. Management of Renal Masses and Localized Renal Cancer. Rockville (MD) 2016.

[59] Marschner N, Staehler M, Muller L, Nusch A, Harde J, Koska M, et al. Survival of Patients With Advanced or Metastatic Renal Cell Carcinoma in Routine Practice Differs From That in Clinical Trials-Analyses From the German Clinical RCC Registry. Clin Genitourin Cancer. 2017;15:e209-e15.

[60] Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T, Pal SK, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014;25:149-54.

[61] Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, et al. First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer. 2016;65:102-8.

[62] Wells JC, Stukalin I, Norton C, Srinivas S, Lee JL, Donskov F, et al. Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2017;71:204-9.
[63] Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, et al. First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer. 2014;110:1917-22.

[64] Beisland C, Johannesen TB, Klepp O, Axelroda U, Torgersen KM, Kowalski J, et al. Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study. Onco Targets Ther. 2017;10:371-85.

[65] Purmonen T, Martikainen JA, Soini EJ, Kataja V, Vuorinen RL, Kellokumpu-Lehtinen PL. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland. Clin Ther. 2008;30:382-92.

[66] Ljungberg B, Gudmundsson E, Christensen S, Lundstam S, Swedish Kidney Cancer Quality Register G. Practice patterns for the surgical treatment of T1 renal cell carcinoma: a nationwide population-based register study. Scand J Urol. 2014;48:445-52.

[67] The British Association of Urological Surgeons section of oncology analyses of nephrectomies performed between January 1st and December 31st 2016. 2017.

[68] Aizer AA, Urun Y, McKay RR, Kibel AS, Nguyen PL, Choueiri TK. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC). BJU Int. 2014;113:E67-74.

[69] Psutka SP, Kim SP, Gross CP, Van Houten H, Thompson RH, Abouassaly R, et al. The impact of targeted therapy on management of metastatic renal cell carcinoma: trends in systemic therapy and cytoreductive nephrectomy utilization. Urology. 2015;85:442-50.

[70] Conti SL, Thomas IC, Hagedorn JC, Chung BI, Chertow GM, Wagner TH, et al. Utilization of cytoreductive nephrectomy and patient survival in the targeted therapy era. Int J Cancer. 2014;134:2245-52.
[71] Tsao CK, Small AC, Kates M, Moshier EL, Wisnivesky JP, Gartrell BA, et al. Cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy in the United States: a SEER analysis. World J Urol. 2013;31:1535-9.

[72] Patel MI, Beattie K, Bang A, Gurney H, Smith DP. Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival. Cancer Med. 2017;6:2188-93.

[73] Hanna N, Sun M, Meyer CP, Nguyen PL, Pal SK, Chang SL, et al. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study. J Clin Oncol. 2016;34:3267-75.

[74] Jeldres C, Baillargeon-Gagne S, Liberman D, Isbarn H, Capitanio U, Shariat SF, et al. A population-based analysis of the rate of cytoreductive nephrectomy for metastatic renal cell carcinoma in the United States. Urology. 2009;74:837-41.

[75] Dabestani S, Beisland C, Stewart GD, Bensalah K, Gudmundsson E, Lam TB, et al. Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis. Eur Urol Focus. 2018.

[76] Maroun R, Mitrofan L, Benjamin L, Nachbaur G, Maounoury F, Le Jeunne P, et al. Real life patterns of care and progression free survival in metastatic renal cell carcinoma patients: retrospective analysis of cross-sectional data. BMC Cancer. 2018;18:214.

[77] Edwards SJ, Wakefield V, Cain P, Karner C, Kew K, Bacelar M, et al. Axitinib, cabozantinib, everolimus, nivolumab, sunitinib and best supportive care in previously treated renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2018;22:1-278.
Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, et al. Pazopanib for the  
first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: a  
NICE single technology appraisal. Pharmacoeconomics. 2013;31:15-24.

Harrison MR, Hirsch BR, George DJ, Walker MS, Chen C, Korytowsky B, et al. Real-world  
outcomes in metastatic renal cell carcinoma: insights from a Joint Community-Academic  
Registry. J Oncol Pract. 2014;10:e63-72.

Hawkins R FK, Hurst M., Gordon J., Naicker N., Wang M. Estimating health outcomes in  
real world patients with advanced or metastatic renal cell carcinoma treated with targeted  
systemic therapy. 13th European International Kidney Cancer Symposium. Prague, Czech  
Republic 2018.

Amdahl J, Diaz J, Sharma A, Park J, Chandiwana D, Delea TE. Cost-effectiveness of  
pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom. PLoS  
One. 2017;12:e0175920.

Motzer RJ, Hutson TE, Cella D, Reeves J, Hawkins R, Guo J, et al. Pazopanib versus  
sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-31.

Fife K CJ, Nolasco S., Matakidou A., Welsh A., Eisen T. Metastatic renal cancer; How  
many patients are we treating? National Cancer Research Institute (NCRI) Cancer  
Conference 2018.

Systemic Anti-Cancer Therapy (SACT) Chemotherapy Dataset. In: England PH,  
editor. 2018.

Camp C, O'Hara J, Hughes D, Adshead J. Short-term Outcomes and Costs Following  
Partial Nephrectomy in England: A Population-based Study. Eur Urol Focus. 2017.

British National Formulary (BNF). In: Committee JF, editor. 74 ed. London: BMJ Group  
and Pharmaceutical Press; 2017.
[87] NICE. NICE technology appraisal TA432: Everolimus for advanced renal cell carcinoma after previous treatment 2017.

[88] NICE. NICE technology appraisal TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment. 2013.

[89] NICE. NICE technology appraisal guidance TA463. Cabozantinib for previously treated advanced renal cell carcinoma. 2017.

[90] NICE. NICE technology appraisal TA417: Nivolumab for previously treated advanced renal cell carcinoma. 2016.

[91] NICE. NICE technology appraisal TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma. 2018.

[92] Curtis L BA. Unit Costs of Health and Social Care 2016. Canterbury: Personal Social Services Research Unit, University of Kent; 2016.

[93] Klinghoffer Z, Tarride JE, Novara G, Ficarra V, Kapoor A, Shayegan B, et al. Cost-utility analysis of radical nephrectomy versus partial nephrectomy in the management of small renal masses: Adjusting for the burden of ensuing chronic kidney disease. Can Urol Assoc J. 2013;7:108-13.

[94] Thompson Coon J, Hoyle M, Green C, Liu Z, Welch K, Moxham T, et al. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation. Health Technol Assess. 2010;14:1-184, iii-iv.

[95] Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.

[96] Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G, Figlin RA, et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and
platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006;24:16-24.

[97] Remak E, Charbonneau C, Negrier S, Kim ST, Motzer RJ. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma. J Clin Oncol. 2008;26:3995-4000.

[98] Calvo Aller E, Maroto P, Kreif N, Gonzalez Larriba JL, Lopez-Brea M, Castellano D, et al. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain. Clin Transl Oncol. 2011;13:869-77.